FDA Approves GSK's Combination Therapy for Treatment of Enlarged Prostate
Posted on: Friday, 20 June 2008, 09:00 CDT
GlaxoSmithKline has announced that the FDA has approved Avodart in combination with tamsulosin for the treatment of symptomatic enlarged prostate, a disease that is said to affect half of all men over 50 years old.
The FDA approval was based on two-year results of the CombAT study, one of the largest clinical trials to date of men with enlarged prostate. The CombAT study is the first long-term assessment of the combination of Avodart and an alpha-blocker, the company said.
The CombAT study results showed that combination therapy with Avodart and tamsulosin was superior to both monotherapies at month 12 and continued to month 24.
Avodart already had been approved by the FDA for the treatment of enlarged prostate to improve urinary symptoms, reduce the risk of acute urinary retention, and reduce the risk of prostate-related surgery. Tamsulosin, an alpha-blocker, also has been indicated for the treatment of the signs and symptoms of enlarged prostate.
Source: Datamonitor
Related Articles
- Philips and Celsion Announce Research Agreement to Develop New Cancer Treatment That Combines Ultrasound, Drug Delivery Technology
- Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
- Researchers at Sarasota Memorial Health Care System to Study Airway Bypass Treatment for Emphysema
- FDA Accepts Akesis Pharmaceuticals' AKP-020 IND Application for a Phase IIa Study in the Treatment of Type 2 Diabetes
- One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
- Idera Pharmaceuticals Presents Interim Data From Phase 1 Study Evaluating IMO-2055 in Combination With Gemcitabine and Carboplatin
- Ablatherm-HIFU Localized Prostate Cancer Clinical Study Resumes at Virginia Urology Center
- Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
- Threshold Pharmaceuticals Completes Enrollment in a Phase 2 Study for the Treatment of Benign Prostatic Hyperplasia
- Novartis's Latest Phase III and II Data With SPP100 (Aliskiren) Reconfirm Speedel's Previous Clinical Studies for the Treatment of Hypertension
User Comments (0)
RSS Feeds